Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (371) clinical trials

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Of note, TGR-1202 has not been associated with treatment related pneumonitis, transaminitis, colitis, PCP-infection nor CMV-reactivation which distinguishes TGR-1202 from idelalisib's toxicity profile. Once the maximum tolerated dose has been safely reached the study will open an expansion cohort to enroll 18 patients with a patient group in which a ...

Phase

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

This trial concerns a novel approach to generating leukaemia antigen-specific T cells for adoptive cellular therapy in HLA-A*0201 patients with acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML) In this study, patient T cells will be gene-modified using a GMP grade retroviral vector containing the genes for a WT1-specific, ...

Phase

Phase I/II Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 3 groups of up to 6 participants will be enrolled in Part 1 of the study, and up ...

Phase

Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia

BACKGROUND AND RATIONALE 1.1. CLINICAL CHARACTERISTICS OF CBF AML Acute myeloid leukemia (AML) is a disease entity consisting of heterogeneous groups with different clinical features and prognosis. Cytogenetic status of patients with AML is the single most important factor to expect the survival and the treatment responses. Core binding factor ...

Phase N/A

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma

PRIMARY OBJECTIVE: I. To determine the seroprotection and seroconversion rates after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation. SECONDARY OBJECTIVES: I. To characterize influenza-specific plasmablasts and memory B cells after influenza vaccination in patients with lymphoma receiving active treatment or in follow up ...

Phase

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Ibrutinib is a selective oral Burton tyrosine kinase inhibitor. Through interfering with the downstream pathways of B-cell receptor signaling, it inhibits proliferation and induces apoptosis in many B-cell lymphoid malignancies. The clinical benefit of ibrutinib has been demonstrated in patients with relapsed/refractory chronic lymphocytic leukaemia, mantle cell lymphoma, small lymphocytic ...

Phase

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

This is an open label phase IB/II clinical trial designed to determine the safety and clinical activity of Ibrutinib in combination with GA101 - Obinutuzumab. Safety, tolerability and dose-limiting toxicities (DLTs) will be evaluated during the initial cycle of treatment (Cycle 1; Day 1-28) as part of the phase Ib ...

Phase

PK PD Safety Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia

This is a two-part study intended to provide investigators and sponsor with the following information regarding the investigational new drug MT-3724: Part 1[COMPLETED]: in patients with relapsed/refractory non-Hodgkin's B cell lymphoma (including SLL) OR relapsed/refractory B-cell CLL The maximum dose of a single course of MT-3724 given as intravenous (IV) ...

Phase

Treosulfan Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

PRIMARY OBJECTIVES: I. Graft failure/rejection and secondary graft failure. II. Day -200 non-relapse mortality. SECONDARY OBJECTIVES: I. Platelet engraftment by six months. II. Grade II-IV and III-IV acute graft-versus-host disease (GVHD) at day 100 and one year. III. Chronic GVHD. IV. Clinically significant infections. V. Overall survival. VI. Relapse or ...

Phase

Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

The purpose of this study is to evaluate the clinical safety and preliminary efficacy of MOR00208 combined with idelalisib or venetoclax. The study will include safety run-in phase for each cohort with an evaluation of the safety data by an Independent Data Monitoring Committee.

Phase